Psychedelics Investing Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression 23 June
psychedelics investing Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference 14 May
psychedelics investing Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights 08 May
